Regeneron Pharmaceuticals (REGN) Current Deferred Tax Assets (2012 - 2015)

Regeneron Pharmaceuticals has reported Current Deferred Tax Assets for 4 years, with the latest figure at $60.5 million in Q3 2015.

• On a quarterly basis, Current Deferred Tax Assets rose 23.5% year-over-year to $60.5 million in Q3 2015; TTM through Sep 2015 was $60.5 million, a 23.5% increase from a year earlier, with the FY2014 full-year figure at $46.2 million, up 3.36% from the prior year.
• Current Deferred Tax Assets was $60.5 million for Q3 2015 at Regeneron Pharmaceuticals, down from $69.6 million in the prior quarter.
• The five-year high for Current Deferred Tax Assets was $148.1 million in Q4 2012, with the low at $36.6 million in Q1 2014.
• Average Current Deferred Tax Assets over 4 years is $61.0 million, with a median of $47.6 million recorded in 2014.
• The sharpest annual moves came in 2013 and 2015: Current Deferred Tax Assets plunged 69.84% in 2013, then surged 86.65% in 2015.
• Over 4 years, Current Deferred Tax Assets stood at $148.1 million in 2012, then plunged by 69.84% to $44.7 million in 2013, then advanced by 3.36% to $46.2 million in 2014, then jumped by 31.06% to $60.5 million in 2015.
• The last three Current Deferred Tax Assets figures came in at $60.5 million (Q3 2015), $69.6 million (Q2 2015), and $62.1 million (Q1 2015), per Business Quant data.